Vascular Biogenics
VBLT

From December 31, 2022: to December 31, 2022 Reclassification of redemption shares into ordinary shares Employee exercise of stock options Share-based compensation to employees and service provider

From December 31, 2020 to December 31, 2021 Issuance of ordinary shares Issuance of ordinary shares, net of issuance costs of $2.2 million Exercised Warrants Issuance of ordinary shares subject to possible redemption

1.Ordinary shares offered 5,150,265 shares. 2.The number of ordinary shares outstanding is based on an aggregate of 48,187,463 ordinary shares outstanding as of December 31, 2020. 3.In addition, the underwriters exercised an option and purchased 1,751,525 additional ordinary shares.

From January 1, 2021 to March 31, 2021 Issuance of ordinary shares, net of issuance costs Exercised warrants

from December 31, 2019 to December 31, 2020 Issuance of ordinary shares and warrants, net of issuance costs of $1,674 thousands

From JANUARY 1, 2020 to SEPTEMBER 30, 2020 SEPTEMBER 30, 2020

from January 1, 2020 to May 27, 2020 Issuance of ordinary shares and warrants, net of issuance costs

from January 1, 2020 to March 31, 2020 Issuance of ordinary shares, net of issuance costs

From DECEMBER 31, 2018 to DECEMBER 31, 2019 Issuance of ordinary shares

From DECEMBER 31, 2017 to October 15,2018 Employee stock options exercised Issuance of ordinary shares and warrants, net of issuance costs in an amount of $1,775 thousand

From JANUARY 1, 2018 to September 30, 2018 Employee stock options exercised Issuance of ordinary shares and warrants, net of issuance costs in an amount of $1,775 thousand

from December 31, 2016 to December 31, 2017 Employee stock options exercised Issuance of ordinary Shares, net of issuance costs of $288 thousand

from December 31, 2015 to December 31, 2016 Employee stock options exercised Issuance of ordinary Shares, net of issuance costs of $2,117 thousand

from December 31, 2014 to December 31, 2015 Employee stock options exercised Issuance of ordinary shares and warrants, net of issuance costs in amount of $1,349 thousand

from January 1, 2015 to September 30, 2015 Employees stock options exercised

from January 1, 2015 to June 30, 2015 Employees stock options exercised

from December 31, 2013 to December 31, 2014 Shares issued and stock options exercised by employees Conversion of preferred shares into ordinary shares Issuance of ordinary shares, net of issuance costs in amount of 5,684 thousand Conversion of convertible loan into preferred E shares Issuance of preferred E shares a 1-to-4.5 forward share split of our shares by way of an issuance of 3.5 bonus shares for each share effective July 10, 2014

Upon the closing of this offering, our authorized share capital will consist solely of 70,000,000 ordinary shares, par value NIS 0.01 per share, of which 19,804,923 shares will be issued and outstanding (assuming that the underwriters do not exercise their option to purchase additional ordinary shares).

gives effect to the sale of 413,096 Series E preferred shares in the company's Series E financing that closed on May 15, 2014; gives effect to the conversion of the company's convertible loan into an aggregate of 1,082,235 Series E preferred shares on May 15, 2014; gives effect to the conversion of all of the company's outstanding preferred shares, including those issued in the Series E financing and upon conversion of the company's convertible loan, into an aggregate of 11,564,897 ordinary shares, which will occur immediately prior to the closing of this offering; gives effect to the issuance of 342,977 ordinary shares immediately prior to the closing of this offering pursuant to anti-dilution rights; gives effect to a 1-to-4.5 forward share split of the company's shares by way of an issuance of 3.5 bonus shares for each share effective July 10, 2014

a 1-to-4.5 forward share split of our shares by way of an issuance of 3.5 bonus shares for each share effective July 10, 2014